Pfizer PFE reported better-than-expected earnings for the third quarter and narrowed its earnings forecast for the year.
Pfizer now expects full-year earnings of $2.23 to $.27 per share, versus its earlier forecast of $2.20 to $2.30 per share. It now expects sales of $48.7 billion to $49.7 billion, versus $48.7 billion to $50.70 billion.
The New York-based company reported a quarterly profit of $2.67 billion, or $0.42 per share, versus a year-ago profit of $2.59 billion, or $0.39 per share. Excluding certain items, the company's earnings declined to $0.57 per share from $0.58 per share.
Its revenue fell 2.2% to $12.36 billion. However, analysts were expecting earnings of $0.55 per share on revenue of $12.24 billion.
Pfizer's global established pharmaceutical segment revenue fell around 7% to $6.24 billion, while global innovative pharmaceutical unit's revenue slipped about 4% to $3.49 billion. Global vaccines revenue climbed 19% to $1.14 billion in the period.
The consumer health-care division's sales surged 4% to $821 million in the quarter.
Frank D'Amelio, Chief Financial Officer, stated, "Overall, I am pleased with our third-quarter 2014 financial results despite the continued negative impact from product losses of exclusivity and the termination of certain co-promotion collaborations.”
Pfizer shares rose 1.51% to $29.55 in pre-market trading.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in